Drug intelligence / Profile preview

IVL3024

Development stage: Preclinical
Lead developer: Inventage Lab
Modality: Peptides
Administration: Subcutaneous

Overview

IVL3024 is a long-acting injectable peptide drug candidate being developed by Inventage Lab in partnership with Yuhan. It functions as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, a mechanism validated for the treatment of metabolic disorders. The candidate utilizes Inventage Lab's proprietary IVL-DrugPol™ microsphere technology to achieve sustained drug release, aiming to provide a more convenient dosing schedule (potentially monthly) compared to existing daily or weekly treatments for type 2 diabetes and obesity.

Targets

GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on IVL3024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVL3024.

Explore the full profile